Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

Background Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (anti-cytotoxi...

Full description

Bibliographic Details
Main Authors: Stephen M Hewitt, David E Kleiner, Tim F Greten, William D Figg, Cecilia Monge, Seth M Steinberg, Maggie Cam, Benjamin Ruf, Austin G Duffy, Jonathan M Hernandez, Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Sophie Wang, Bradford J Wood, Elliot B Levy, Israa Juburi, Bernadette Redd, Philip Homan
Format: Article
Language:English
Published: BMJ Publishing Group 2023-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/2/e005640.full

Internet

https://jitc.bmj.com/content/11/2/e005640.full

Similar Items